443 related articles for article (PubMed ID: 31694584)
1. Quality of life assessment in patients with heart failure: validity of the German version of the generic EQ-5D-5L™.
Boczor S; Daubmann A; Eisele M; Blozik E; Scherer M
BMC Public Health; 2019 Nov; 19(1):1464. PubMed ID: 31694584
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors associated with quality of life in heart failure patients considering the use of the generic EQ-5D-5L™ in primary care: new follow-up results of the observational RECODE-HF study.
Boczor S; Eisele M; Rakebrandt A; Menzel A; Blozik E; Träder JM; Störk S; Herrmann-Lingen C; Scherer M;
BMC Fam Pract; 2021 Oct; 22(1):202. PubMed ID: 34645408
[TBL] [Abstract][Full Text] [Related]
3. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
4. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
[TBL] [Abstract][Full Text] [Related]
5. Validity and measurement equivalence of EQ-5D-5L questionnaire among heart failure patients in Malaysia: a cohort study.
Kuan WC; Chee KH; Kasim S; Lim KK; Dujaili JA; Lee KK; Teoh SL
J Med Econ; 2024; 27(1):607-617. PubMed ID: 38557412
[TBL] [Abstract][Full Text] [Related]
6. The use of the EQ-5D-Y health related quality of life outcome measure in children in the Western Cape, South Africa: psychometric properties, feasibility and usefulness - a longitudinal, analytical study.
Scott D; Ferguson GD; Jelsma J
Health Qual Life Outcomes; 2017 Jan; 15(1):12. PubMed ID: 28103872
[TBL] [Abstract][Full Text] [Related]
7. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients.
Golicki D; Niewada M; Karlińska A; Buczek J; Kobayashi A; Janssen MF; Pickard AS
Qual Life Res; 2015 Jun; 24(6):1555-63. PubMed ID: 25425288
[TBL] [Abstract][Full Text] [Related]
8. Quality of life assessment in diabetic patients: validity of the creole version of the EQ-5D-5L in Reunion Island.
Safieddine M; Bruneau L; Soulaimana I; Debussche X; Lafarge S; Falissard B; Ferdynus C; Huiart L
Front Psychol; 2023; 14():1185316. PubMed ID: 37397299
[TBL] [Abstract][Full Text] [Related]
9. Performance of the EQ-5D in patients with irritable bowel syndrome.
Bushnell DM; Martin ML; Ricci JF; Bracco A
Value Health; 2006; 9(2):90-7. PubMed ID: 16626412
[TBL] [Abstract][Full Text] [Related]
10. Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa.
Gergely LH; Gáspár K; Brodszky V; Kinyó Á; Szegedi A; Remenyik É; Kiss NF; Bató A; Péntek M; Gulácsi L; Sárdy M; Bánvölgyi A; Wikonkál N; Rencz F
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2584-2592. PubMed ID: 32618022
[TBL] [Abstract][Full Text] [Related]
11. Psychometrics and validation of the EQ-5D-5L instrument in individuals with ischemic stroke in Lithuania.
Taroza S; Burkauskas J; Mickuviene N; Kazukauskiene N; Podlipskyte A
Front Psychol; 2023; 14():1284859. PubMed ID: 38125861
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison between the EQ-5D-5L and the EQ-5D-3L in general population health surveys.
Martí-Pastor M; Pont A; Ávila M; Garin O; Vilagut G; Forero CG; Pardo Y; Tresserras R; Medina-Bustos A; Garcia-Codina O; Cabasés J; Rajmil L; Alonso J; Ferrer M
Popul Health Metr; 2018 Aug; 16(1):14. PubMed ID: 30115092
[TBL] [Abstract][Full Text] [Related]
13. Psychometric properties of the EQ-5D-5L for aboriginal Australians: a multi-method study.
Ribeiro Santiago PH; Haag D; Macedo DM; Garvey G; Smith M; Canfell K; Hedges J; Jamieson L
Health Qual Life Outcomes; 2021 Mar; 19(1):81. PubMed ID: 33691744
[TBL] [Abstract][Full Text] [Related]
14. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
15. [Development of the German version of EQ-5D-Y-5L to measure health-related quality of life in children and adolescents: Identification of response labels and pilot testing].
Kreimeier S; Greiner W
Z Evid Fortbild Qual Gesundhwes; 2019 Aug; 144-145():24-34. PubMed ID: 31378708
[TBL] [Abstract][Full Text] [Related]
16. Reliability, Validity and Responsiveness of the EQ-5D-5L in Assessing and Valuing Health Status in Adolescents and Young Adults with Posttraumatic Stress Disorder: a Randomized Controlled Trail.
Dams J; Rimane E; Steil R; Renneberg B; Rosner R; König HH
Psychiatr Q; 2021 Jun; 92(2):459-471. PubMed ID: 32803473
[TBL] [Abstract][Full Text] [Related]
17. Discriminative validity of the EQ-5D-5 L and SF-12 in older adults with arthritis.
Tawiah AK; Al Sayah F; Ohinmaa A; Johnson JA
Health Qual Life Outcomes; 2019 Apr; 17(1):68. PubMed ID: 30995930
[TBL] [Abstract][Full Text] [Related]
18. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
19. Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis.
Gualtierotti R; Ingegnoli F; Scalone L; Cortesi P; Bruschi E; Gerosa M; Meroni PL
Swiss Med Wkly; 2016; 146():w14394. PubMed ID: 28102877
[TBL] [Abstract][Full Text] [Related]
20. Validation of the arabic version of the EuroQol-5-dimension 5-level (EQ-5D-5 L) in patients with spinal degenerative diseases.
Shawky Abdelgawaad A; El-Sharkawi M; Sarhan AM; Hassanien MA; Aziz M
BMC Public Health; 2024 Apr; 24(1):1119. PubMed ID: 38654180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
